©2024 Stanford Medicine
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Not Recruiting
Trial ID: NCT01659021
Purpose
The primary objective of this study is to evaluate the effect of the addition of idelalisib
to ofatumumab on progression-free survival (PFS) in participants with previously treated
chronic lymphocytic leukemia (CLL).
Official Title
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Eligibility
Key Inclusion Criteria:
- Adults with previously treated recurrent CLL who have measurable lymphadenopathy
- Require therapy for CLL
- Have experienced CLL progression < 24 months since the completion of the last prior
therapy
- Have disease that is not refractory to ofatumumab
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention(s):
drug: Ofatumumab
drug: Idelalisib
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061